20200622a – Transgene PR AACR 3 posters
Category: 2020
Combined General Meeting of May 27, 2020
20200527 TG AGM 2020
Transgene and BioInvent present preclinical data demonstrating BT-001’s powerful activity against solid tumors
20200515 BT-001_AACR curtain raiser EN
Transgene and NEC demonstrate high accuracy of AI-based neoantigen prediction for the design of individualized cancer vaccine TG4050
20200515_AACR myvac curtain raiser EN
Transgene reports Q1 2020 financial position and business update
20200506 TG FINANCIAL T1- US
Vaxxel acquires Transgene’s DuckCelt®-T17 cell line to develop industrial-scale vaccines against respiratory viruses
20200504 – TG Vaxxell EN
Availability of Transgene’s 2019 Universal Registration Document and update on the effect of Covid-19
20200402PR-EN availability URD 2019
Availability of Preparatory Documents for the Combined General Meeting of May 27, 2020
20200403 – availability doc AG – EN
Major R&D milestones achieved in 2019 and strong clinical activity in 2020
20200311 Resultats 2019 EN
BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment
Poster BT-001Marchand, Semmrich, Fend et al.Immuno-Oncology summitDownload the poster herePoster Presentation
